Article Text

Download PDFPDF
Change in cartilage morphometry: a sample of the progression cohort of the Osteoarthritis Initiative
  1. D J Hunter1,2,
  2. J Niu2,
  3. Y Zhang2,
  4. S Totterman3,
  5. J Tamez3,
  6. C Dabrowski4,
  7. R Davies4,
  8. M-P Hellio Le Graverand5,
  9. M Luchi6,
  10. Y Tymofyeyev7,
  11. C R Beals7,
  12. for the OAI Investigators
  1. 1
    Division of Research, New England Baptist Hospital, Boston, Massachusetts, USA
  2. 2
    Boston University School of Medicine at Boston Medical Center, Boston, Massachusetts, USA
  3. 3
    VirtualScopics, Rochester, New York, USA
  4. 4
    Musculoskeletal Medicines Development Center, GlaxoSmithKline Pharmaceutical Company, Collegeville, Pennsylvania, USA
  5. 5
    Pfizer, Global Research and Development, Ann Arbor, Michigan, USA
  6. 6
    Novartis, East Hanover, New Jersey, USA
  7. 7
    Merck Research Laboratories, Rahway, New Jersey, USA
  1. Dr D J Hunter at Division of Research, New England Baptist Hospital, 125 Parker Hill Ave, Boston, MA 02120, USA; djhunter{at}


Objective: The performance characteristics of hyaline articular cartilage measurement on magnetic resonance imaging (MRI) need to be accurately delineated before widespread application of this technology. Our objective was to assess the rate of natural disease progression of cartilage morphometry measures from baseline to 1 year in knees with osteoarthritis (OA) from a subset of participants from the Osteoarthritis Initiative (OAI).

Methods: Subjects included for this exploratory analysis are a subset of the approximately 4700 participants in the OAI Study. Bilateral radiographs and 3T MRI (Siemans Trio) of the knees and clinical data were obtained at baseline and annually in all participants. 160 subjects from the OAI Progression subcohort all of whom had both frequent symptoms and, in the same knee, radiographic OA based on a screening reading done at the OAI clinics were eligible for this exploratory analysis. One knee from each subject was selected for analysis. 150 participants were included. Using sagittal 3D DESSwe (double echo, steady-state sequence with water excitation) MR images from the baseline and 12 follow-up month visit, a segmentation algorithm was applied to the cartilage plates of the index knee to compute the cartilage volume, normalised cartilage volume (volume normalised to bone surface interface area), and percentage denuded area (total cartilage bone interface area denuded of cartilage).

Results: Summary statistics of the changes (absolute and percentage) from baseline at 1 year and the standardised response mean (SRM), ie, mean change divided by the SD change were calculated. On average the subjects were 60.9 years of age and obese, with a mean body mass index of 30.3 kg/m2. The SRMs for cartilage volume of various locations are: central medial tibia −0.096; central medial femur −0.394; and patella −0.198. The SRMs for normalised cartilage volume of the various locations are central medial tibia −0.044, central medial femur −0.338 and patella −0.193. The majority of participants had a denuded area at baseline in the central medial femur (62%) and central medial tibia (60%). In general, the SRMs were small.

Conclusions : These descriptive results of cartilage morphometry and its change at the 1-year time point from the first substantive MRI data release from the OAI Progression subcohort indicate that the annualised rates of change are small with the central medial femur showing the greatest consistent change.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests: None.

  • Funding: The OAI is a public–private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health.

  • The Osteoarthritis Initiative and this pilot study are conducted and supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (N01-AR-2-2262, N01-AR-2-2262, N01-AR-2-2258) in collaboration with the OAI Investigators and Consultants. This manuscript has been reviewed by the OAI Publication committee for scientific content and data interpretation.

  • ▸ An additional appendix is published online only at